MA55082A - Compositions, procédés, et kits pour l'administration de polyribonucléotides - Google Patents

Compositions, procédés, et kits pour l'administration de polyribonucléotides

Info

Publication number
MA55082A
MA55082A MA055082A MA55082A MA55082A MA 55082 A MA55082 A MA 55082A MA 055082 A MA055082 A MA 055082A MA 55082 A MA55082 A MA 55082A MA 55082 A MA55082 A MA 55082A
Authority
MA
Morocco
Prior art keywords
polyribonucleotides
kits
administration
compositions
methods
Prior art date
Application number
MA055082A
Other languages
English (en)
Inventor
Ellese Marie Carmona
Boer Alexandra Sophie De
Roger Joseph Hajjar
Avak Kahvejian
Nicholas Mccartney Plugis
Morag Helen Stewart
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MA55082A publication Critical patent/MA55082A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055082A 2019-03-01 2020-03-01 Compositions, procédés, et kits pour l'administration de polyribonucléotides MA55082A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962812763P 2019-03-01 2019-03-01

Publications (1)

Publication Number Publication Date
MA55082A true MA55082A (fr) 2022-01-05

Family

ID=70005812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055082A MA55082A (fr) 2019-03-01 2020-03-01 Compositions, procédés, et kits pour l'administration de polyribonucléotides

Country Status (9)

Country Link
US (1) US20220088049A1 (fr)
EP (1) EP3930683A1 (fr)
JP (2) JP7526195B2 (fr)
CN (1) CN113543770A (fr)
AU (1) AU2020231349B2 (fr)
CA (1) CA3128615A1 (fr)
IL (1) IL285923A (fr)
MA (1) MA55082A (fr)
WO (1) WO2020180751A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006150A (es) 2017-12-15 2020-11-11 Flagship Pioneering Innovations Vi Llc Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
JP7618577B2 (ja) 2019-03-25 2025-01-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 修飾環状ポリリボヌクレオチドを含む組成物及びその使用
US12636369B2 (en) 2019-06-19 2026-05-26 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
WO2021236952A1 (fr) * 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions et procédés de production d'anticorps polyclonaux humains
AR127073A1 (es) 2021-09-17 2023-12-13 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
MX2024006407A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones de inmunogenos del virus varicela-zoster y sus usos.
IL312965A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and their uses
WO2023096990A1 (fr) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Compositions immunogènes de coronavirus et leurs utilisations
CN118510896A (zh) 2021-12-17 2024-08-16 旗舰创业创新六公司 用于在变性条件下富集环状rna的方法
AU2022420620A1 (en) 2021-12-23 2024-07-04 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
JP2026503676A (ja) 2023-01-27 2026-01-29 セイル バイオメディシンズ インコーポレイテッド 修飾脂質組成物およびその使用
EP4680750A1 (fr) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Compositions comprenant des polyribonucléotides et leurs utilisations
EP4680276A1 (fr) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Compositions immunogènes et leurs utilisations
WO2025006684A1 (fr) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Polyribonucléotides circulaires codant pour des polypeptides antifusogènes
WO2025240369A2 (fr) * 2024-05-13 2025-11-20 Helix Nanotechnologies Inc Procédés de distribution de polyribonucléotides nus
WO2026096919A1 (fr) 2024-11-01 2026-05-07 Sail Biomedicines, Inc. Nouveaux lipides à cœur dipeptidique, vecteurs lipidiques et méthodes d'utilisation de ceux-ci
WO2026152164A1 (fr) 2025-01-13 2026-07-16 Sail Biomedicines, Inc. Nanoparticules lipidiques ciblant cd5 encapsulant des polyribonucléotides codant pour des récepteurs antigéniques chimériques, et méthodes de génération in vivo de lymphocytes t exprimant un récepteur antigénique chimérique

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
US4283393A (en) * 1979-03-13 1981-08-11 Merck & Co., Inc. Topical application of interferon inducers
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
AU649066B2 (en) 1990-07-25 1994-05-12 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
JPH0558866A (ja) * 1991-08-28 1993-03-09 Lion Corp 口腔用組成物
EP0604552B1 (fr) 1991-09-18 1997-02-12 Affymax Technologies N.V. Procede de synthese de diverses collections d'oligomeres
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
AU683011B2 (en) 1992-01-13 1997-10-30 Duke University Enzymatic RNA molecules
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5721099A (en) 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5440016A (en) 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5688997A (en) 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5688696A (en) 1994-12-12 1997-11-18 Selectide Corporation Combinatorial libraries having a predetermined frequency of each species of test compound
CA2225313A1 (fr) 1995-06-21 1997-01-09 Martek Biosciences Corporation Banques combinatoires de composes biochimiques marques et procedes de production de telles banques
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US5731423A (en) 1996-03-21 1998-03-24 Transcell Technologies, Inc. Process for preparing sulfoxides
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
US7334580B2 (en) 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
KR101033097B1 (ko) 2002-05-07 2011-05-06 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 표적 기관지내 요법을 위한 방법, 장치 및 제제
DE102004025881A1 (de) * 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
CN101060864A (zh) * 2004-09-21 2007-10-24 阿尼西瓦股份有限公司 多核苷酸的递送
CA2583413A1 (fr) * 2004-09-21 2006-03-30 Anesiva, Inc. Administration de polynucleotides
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1968643A2 (fr) 2005-12-16 2008-09-17 Diatos Conjugués peptidiques de pénétration cellulaire pour la délivrance d'acides nucléiques dans une cellule
JP5295785B2 (ja) 2006-02-20 2013-09-18 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
US8431692B2 (en) * 2008-06-06 2013-04-30 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
WO2010084371A1 (fr) 2009-01-26 2010-07-29 Mitoprod Nouvelles molécules d'arn interférent circulaire
EP3391877A1 (fr) * 2010-04-08 2018-10-24 The Trustees of Princeton University Préparation de nanoparticules lipidiques
NZ704191A (en) 2010-06-14 2016-05-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
KR101938548B1 (ko) * 2011-06-23 2019-01-15 (주)아모레퍼시픽 마이크로 ｒｎａ를 포함하는 색소형성유전자 발현조절용 조성물
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
WO2013053481A1 (fr) * 2011-10-11 2013-04-18 Secutech International Pte. Ltd. Diméthylsulfoxyde utilisé comme solvant pour des acides nucléiques
ES2923757T3 (es) * 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
US10501512B2 (en) * 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US20170281541A1 (en) 2014-09-05 2017-10-05 The Johns Hopkins University Liposome-based mucus-penetrating particles for mucosal delivery
US11241505B2 (en) * 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
HRP20220156T1 (hr) * 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
CN105664239B (zh) * 2016-03-23 2018-08-07 成都交大麦迪克科技有限公司 一种自粘附皮肤修复水凝胶的制备方法
WO2017222911A1 (fr) * 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Arn circulaires et leur utilisation dans l'immunomodulation
RU2019121801A (ru) 2016-12-14 2021-01-15 Лигандал, Инк. Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
JP7209951B2 (ja) * 2017-10-30 2023-01-23 日本メナード化粧品株式会社 白髪予防及び改善剤

Also Published As

Publication number Publication date
CA3128615A1 (fr) 2020-09-10
JP7526195B2 (ja) 2024-07-31
KR20210134716A (ko) 2021-11-10
AU2020231349B2 (en) 2025-10-23
IL285923A (en) 2021-10-31
EP3930683A1 (fr) 2022-01-05
WO2020180751A1 (fr) 2020-09-10
JP2022523222A (ja) 2022-04-21
CN113543770A (zh) 2021-10-22
JP2024147750A (ja) 2024-10-16
US20220088049A1 (en) 2022-03-24
AU2020231349A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3894343A4 (fr) Procédés et compositions pour l'administration de dioxyde de carbone
EP3874030A4 (fr) Compositions et procédés pour l'ingénierie des lymphocytes t
EP3938528A4 (fr) Procédés et compositions pour le diagnostique de la dépression
MA53445A (fr) Procédés et compositions pour la modification de plantes
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
EP3893655A4 (fr) Procédés pour la préparation d'un composition de protéines végétales
EP3826468A4 (fr) Compositions pour l'agriculture et procédés associés
EP4009778A4 (fr) Procédés et compositions pour la production de mycéliums ectomycorhiziens et leurs procédés d'utilisation
EP3630962A4 (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
EP3519572A4 (fr) Composés et procédés pour réduire l'expression de tau
EP3856742A4 (fr) Inhibiteurs de janus kinase 1 tricycliques, et compositions et procédés associés
EP3891272A4 (fr) Compositions et procédés d'immunothérapie
EP3793562A4 (fr) Procédés et compositions pour inhiber la dihydroorotate déshydrogénase
EP3735457A4 (fr) Compositions et procédés pour produire des mégacaryocytes
EP3648773A4 (fr) Composés et procédés pour l'administration transmembranaire de molécules
EP3432872A4 (fr) Compositions et méthodes pour l'utilisation d'éflornithine et de dérivés et analogues de cette dernière pour le traitement de cancers, dont les gliomes
EP3853352A4 (fr) Plaque de puits fonctionnalisée, procédés de préparation et d'utilisation de celle-ci
EP3814429A4 (fr) Compositions d'asphalte et procédés pour les former
EP4058062A4 (fr) Compositions et méthodes pour l'immunothérapie
MA46431A (fr) Composés et procédés pour réduire l'expression de tau
EP4137643C0 (fr) Ensemble d'usure
EP3624838A4 (fr) Procédés d'utilisation de cd24 soluble pour la neuroprotection et la remyélinisation
EP3994214A4 (fr) Procédés d'accélération du durcissement de compositions de silicone
EP3950864A4 (fr) Composition d'apprêt